Rapamycin induces a caspase-independent cell death in human monocytes

American Journal of Transplantation

Volumn 6, Issue 6, 2006, Pages 1331-1341

  Mercalli, A ^a   Sordi, V ^a   Ponzoni, M ^a   Maffi, P ^a   De Taddeo, F ^a   Gatti, G ^a   Servida, P ^b   Bernardi, M ^b   Bellio, L ^b   Bertuzzi, F ^a   Secchi, A ^a   Bonifacio, E ^a   Piemonti, L ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Apoptosis; Inflammation; Rapamycin

Indexed keywords

CASPASE; CD14 ANTIGEN; CD15 ANTIGEN; CD16 ANTIGEN; CD33 ANTIGEN; CYTOKINE; DACLIZUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; TOLL LIKE RECEPTOR 4;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CELL DEATH; CELL LINEAGE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; MONOCYTE; MONOTHERAPY; MYELOID PROGENITOR CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN FAMILY; UNSPECIFIED SIDE EFFECT;

ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CASPASES; CELL DEATH; CELL SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MONOCYTES; SIROLIMUS;

EID: 33745854501     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01332.x     Document Type: Article

References (63)

1. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727-732.
2. Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993; 154: 7-15.
3. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58: 373-395.
4. Aagaard-Tillery KM, Jelinek DF. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 1994; 156: 493-507.
5. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: An overview. Liver Transpl 2001; 7: 473-484.
6. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22(Suppl B): B101-B121.
7. Sehgal SN. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995; 17: 660-665.
8. Calne RY, Collier DS, Lim S et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
9. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
10. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
11. Vasquez EM. Sirolimus: A new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000; 57: 437-448; quiz 449-451.
12. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
13. Salazar A, McAlister VC, Kiberd BA, Bitter-Suermann H, Al-Kerithy MF, MacDonald AS. Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: Effect on renal function. Transplant Proc 2001; 33: 1038-1039.
14. Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001; 71: 1400-1406.
15. Trotter JF, Wachs ME, Trouillot TE et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7: 401-408.
16. Snell GI, Levvey BJ, Chin W et al. Rescue therapy: A role for sirolimus in lung and heart transplant recipients. Transplant Proc 2001; 33: 1084-1085.
17. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262.
18. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37: 19-24.
19. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
20. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996; 56: 3895-3897.
21. Brunn GJ, Hudson CC, Sekulic A et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277: 99-101.
22. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680-6686.
23. Sousa JE, Costa MA, Abizaid AC et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-2011.
24. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
25. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 55: 1982-1988.
26. Hosoi H, Dilling MB, Shikata T et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999; 59: 886-894.
27. Garber K. Rapamycin's resurrection: A new way to target the cancer cell cycle. J Natl Cancer Inst 2001; 93: 1517-1519.
28. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001; 98: 10314-10319.
29. Podsypanina K, Lee RT, Politis C et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten± mice. Proc Natl Acad Sci U S A 2001; 98: 10320-10325.
30. Peralba JM, DeGraffenried L, Friedrichs W et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003; 9: 2887-2892.
31. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
32. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995; 60: 264-270.
33. Hultsch T, Martin R, Hohman RJ. The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. Mol Biol Cell 1992; 3: 981-987.
34. O'Gorman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 2000; 14: 602-611.
35. Yamamoto-Yamaguchi Y, Okabe-Kado J, Kasukabe T, Honma Y. Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors. Exp Hematol 2001; 29: 582-588.
36. Decker T, Hipp S, Ringshausen I et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003; 101: 278-285.
37. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972-980.
38. Bell E, Cao X, Moibi JA et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52: 2731-2739.
39. Baumer W, Sulzle B, Weigt H et al. Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis. Br J Dermatol 2005; 153: 136-144.
40. Beriou G, Peche H, Guillonneau C, Merieau E, Cuturi MC. Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression. Transplantation 2005; 79: 969-972.
41. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5: 228-236.
42. Hackstein H, Taner T, Zahorchak AF et al. Rapamycin inhibits IL-4 - Induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457-4463.
43. Monti P, Mercalli A, Leone BE, Valerio DC, Allavena P, Piemonti L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003; 75: 137-145.
44. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003; 101: 1439-1445.
45. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084-1087.
46. Woltman AM, de Fijter JW, Kamerling SW et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001; 98: 174-180.
47. Ryan EA, Lakey JR, Paty BW et al. Successful islet transplantation: Continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51: 2148-2157.
48. Bauermeister DE. Quantitation of bone marrow reticulin - A normal range. Am J Clin Pathol 1971; 56: 24-31.
49. Leist M, Jaattela M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589-598.
50. Chipuk JE, Green DR. Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol 2005; 6: 268-275.
51. Abraham MC, Shaham S. Death without caspases, caspases without death. Trends Cell Biol 2004; 14: 184-193.
52. Lockshin RA, Zakeri Z. Caspase-independent cell death? Oncogene 2004; 23: 2766-2773.
53. Guthridge MA, Stomski FC, Thomas D et al. Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells 1998; 16: 301-313.
54. de Groot RP, Coffer PJ, Koenderman L. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal 1998; 10: 619-628.
55. Kinoshita T, Yokota T, Arai K, Miyajima A. Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors. Embo J 1995; 14: 266-275.
56. Mangan DF, Welch GR, Wahl SM. Lipopolysaccharide, tumor necrosis factor-alpha, and IL-1 beta prevent programmed cell death (apoptosis) in human peripheral blood monocytes. J Immunol 1991; 146: 1541-1546.
57. Mangan DF, Wahl SM. Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol 1991; 147: 3408-3412.
58. Bohm J. Gelatinous transformation of the bone marrow: The spectrum of underlying diseases. Am J Surg Pathol 2000; 24: 56-65.
59. Sugatani T, Hruska KA. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005; 280: 3583-3589.
60. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10: 1165-1177.
61. Lambert M, Hubert C, Depresseux G et al. Hematological changes in anorexia nervosa are correlated with total body fat mass depletion. Int J Eat Disord 1997; 21: 329-334.
62. Lehman JA, Calvo V, Gomez-Cambronero J. Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils: Cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, mTOR-related THR389 kinase. J Biol Chem 2003; 278: 28130-28138.
63. Blommaart EF, Luiken JJ, Blommaart PJ, van Woerkom GM, Meijer AJ. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem 1995; 270: 2320-2326.